The alpha 2 (r) interferon in the treatment of hairy cell leukemia: progressive report of 25 cases.
Twenty-five patients with Hairy Cell Leukemia (HCL), eleven in post-splenectomy progressive disease, have been treated as out-patients with alpha 2 (r) Interferon (IFN) for twelve months. Eighteen patients completed the treatment: four achieved Complete Response (CR), twelve Partial Response (PR) and two Minor Response (MR). The response to IFN has been CR or PR in 89% of cases and MR in 11%. Even if the IFN effective dose and the length of treatment remain to be determined, IFN at relatively low dose seems to become the first treatment of choice in HCL patients. The remaining seven patients, still under treatment, already achieved PR at least.
Mandelli
F
F
Department of Human Biopathology, University La Sapienza Rome, Italy.
Cafolla
A
A
Annino
L
L
Amadori
S
S
Gentile
A
A
Bianco
P
P
Dianzani
F
F
D000328:Adult; D000368:Aged; D001707:Biopsy, Needle; D001856:Bone Marrow Examination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D007943:Leukemia, Hairy Cell / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011994:Recombinant Proteins
D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins